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Summary. Background. The frequency of B19 infection in renal transplant donors and recipi-
ents was studied to determine the significance of active viral infection in the development of anemia.
Material and Methods. Serum, plasma, and peripheral blood leukocyte samples of 47 renal 
transplant donors, 38 recipients with anemia (Group 1), and 25 without anemia (Group 2) after 
renal transplantation were evaluated for the presence of anti-B19 specific antibodies (ELISA) and 
B19 DNA (nPCR).
Results. Active persistent B19 infection after renal transplantation was detected in 12 of the 
38 in the Group 1 (10 had reactivation and 2 primary infection), and none of the recipients in the 
Group 2 had it. Of the 12 recipients in the Group 1, 10 were seropositive and 2 seronegative before 
renal transplantation; 10 received the transplants from the seropositive and 2 from seronegative 
donors. rHuEPO therapy-resistant severe anemia was detected only in the recipients with active 
B19 infection after renal transplantation in the Group 1 (7/12). The logistic regression analysis 
revealed a significant relationship between active B19 infection and severe anemia (OR, 0.039; 95% 
CI, 0.006–0.257; P=0.001).
Conclusions. Active B19 infection was documented only in the anemic recipients and could be 
associated with the development of severe anemia after renal transplantation. This allows us to 
recommend concurrent screening for viral DNA in plasma and detection of anti-B19 IgM class 
antibodies. To find the association between B19 infection and the development of anemia, further 
investigations are necessary.
Correspondence to S. Čapenko, A. Kirchenstein Institute of 
Microbiology and Virology, Riga Stradins University, Ratsu-
pites 5, 1067 Riga, Latvia. E-mail: scapenko@latnet.lv
Introduction
Human parvovirus B19 (B19) was first discov-
ered by Cossart et al. in the sera of healthy blood 
donors (1). The virus is ubiquitous, and the course 
of infection depends on the host’s hematological sta-
tus and immunologic response. A cellular receptor 
for B19 is globoside (blood group P antigen), which 
is expressed on erythroid progenitor cells (the site 
of virus replication), megakaryocytes, tissue cells of 
the heart, liver, lung, kidney, endothelium, aortic 
and gastrointestinal smooth muscle, and synovium 
(2, 3). The distribution of P antigen across tissues 
may explain the clinical manifestation of viral infec-
tion. 
B19 encodes 3 major viral proteins: VP1 and 
VP2, the viral capsid proteins, and NS1, a non-
structural protein (4). The VP proteins contain the 
domains to which virus-neutralizing antibodies are 
directed (5). The appearance of antibodies to B19 
is associated with the clearance of the virus from 
bloodstream; however, the high frequency of persis-
tence of B19 DNA in the tissues of healthy persons 
under the presence of anti-B19 antibodies indicates 
that complete eradication of the virus from host 
body has not occurred (6, 7). In immunocompro-
mised patients, such as renal transplant recipients, 
who are unable to mount a neutralizing antibody 
response, persistent viral infection may result in 
the chronic suppression of erythropoiesis with the 
development of chronic anemia or lead to B19-re-
lated recurrent anemia (8–12) and a renal allograft 
dysfunction; however, a causal relationship has not 
been definitively established yet (13, 14). The di-
agnosis of B19 infection is based on clinical data, 
morphological evaluation of peripheral blood and 
bone marrow specimens, and detection of specific 
antiviral antibodies and viral genomic sequences in 
peripheral blood leukocytes (PBL) and plasma DNA 
(15, 16).
Chronic anemia is a major problem in renal 
transplant patients. The treatment of anemic pa-
tients with high doses of intravenous immuno-
globulin (IVIG) combined with the reduction of 
immunosuppression may result in the improvement 
of symptomatic infection (12), but not in B19 eradi-
cation (7). The frequency of B19 infection in renal 
transplant donors and recipients is underestimated 
due to the lack of routine clinical diagnostics for it, 
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and anemia is often ascribed to immunosuppressive 
drugs. 
The aim of our study was to investigate the fre-
quency of B19 infection in renal transplant donors 
and patients before and after renal transplantation 
(RT) and to determine the significance of active vi-
ral infection in the development of anemia. 
Material and Methods
Patients. A total of 47 renal transplant donors and 
their 63 recipients (29 men and 34 women; mean 
age, 49 years [SD, 6.7]) were enrolled in this study. 
The study was retrospective, and only recipients 
with complete clinical data were included under-
went virological examination. The patients received 
renal transplants from deceased persons at the Trans-
plantation Centre of Pauls Stradins Clinical University 
Hospital in Riga between January 2000 and December 
2003. The mean follow-up was 35 months (SD, 7.8). 
The patients after RT were divided in 2 groups ac-
cording to the hemoglobin (Hb) level: the Group 1 in-
cluded 38 patients with anemia and Group 2 (control) 
included 25 patients without anemia during 3 months 
after RT and entire follow-up (Table 1). Anemia (Hb 
level, <13.5 g/dL for male and <12 g/dL, for women) 
was defined according to the National Kidney Foun-
dation KDOQI Guidelines (The Clinical Practice 
Guidelines and Clinical Practice Recommendations 
for Anaemia in Chronic Kidney Disease, 2006). 
Moderate anemia was arbitrarily defined as an Hb 
level of 12–10 g/dL for males and 11–10 g/dL for 
females, and severe grade anemia, as an Hb level of 
<10 g/dL for both genders. 
Initial immunosuppression in all patients in-
cluded cyclosporine (CsA), mycophenolate mofetil 
(MMF), and prednisolone (P), but the patients who 
were considered to be at moderate and high im-
munological risk of acute rejection (AR) received 
also induction with IL-2R monoclonal antibodies 
(Basiliximab). Maintenance immunosuppression 
included CsA, MMF, and P. The treatment with 
oral CsA in microemulsion was initiated before sur-
gery (10 mg/kg per day) to obtain therapeutic CsA 
blood levels and then was adjusted based on target 
through levels 150–250 ng/mL during the first 4 
weeks and at 150–200 ng/mL thereafter. The CsA 
level was measured using an AxSym (Abbott) cy-
closporine fluorescence polarization immunoassay. 
The maintenance dosage of orally administered 
MMF was 1.0–2.0 g per day. Methylprednisolone 
(MP) was administered at a dosage of 5.0 mg/kg per 
day on 3 consecutive days from the first day of RT. 
The administration of oral P was initiated at a dos-
age of 0.5 mg/kg per day on the first day after op-
eration and reduced gradually to 5.0–10 mg per day. 
AR episodes were identified based on characteristic 
clinical features and were confirmed by percutane-
ous biopsy. The histological features were graded 
according to the Banff 97 classification. AR epi-
sodes were treated with intravenous MP at a dosage 
of 500 mg/day for 3 days. Steroid-resistant cases 
were treated with antithymocyte globulin (ATG) at 
a dosage of 4 mg/kg for 7–10 days. A delayed graft 
function was estimated based on serum creatinine 
concentration (>0.2 mmol/L). 
The serum, PBL, and cell-free plasma samples 
were taken from the donors and all patients before 
and after RT. The EDTA-anti-coagulated peripheral 
blood, serum, and plasma samples were stored at 
–70°C.
This retrospective study was performed with the 
permission of Local Ethics Committee, and all the 
participants gave informed consent before the ex-
amination.
Detection of B19 Genomic Sequences by Nested 
Polymerase Chain Reaction. B19 DNA analysis was 
carried out in the samples from PBL to detect per-
sistent viral infection and cell-free plasma to de-
tect plasma viremia (PV). Total DNA was purified 
by proteinase K digestion overnight and extraction 
by a standard phenol-chloroform technique. To as-
sure the quality of PBL DNA and to exclude a pos-
sible contamination of plasma by cellular DNA, a 
β-globin gene polymerase chain reaction was car-
ried out. B19 genomic DNA was detected by a 
nested polymerase chain reaction (nPCR) assay that 
amplified the VP1 region as described before (10). 
PCR amplification was performed in the presence of 
1 µg of PBL DNA and 10 µL of plasma DNA (corre-
sponding to 100 µL of plasma). B19-negative DNA 
was used as a negative control, and DNA from the 
viremic serum (kindly provided by Prof. K. Hed-
man, Hartman Institute, Department of Virology, 
University of Helsinki) was used as a positive con-
trol. Water controls were included after every third 
sample in each experiment.
Detection of B19 anti-VP2 Specific Antibodies. 
Serum samples of donors as well as pre- and post-
transplants from the patients were tested for B19-
specific IgG and IgM class antibodies using a sand-
wich enzyme immunosorbent assay (ELISA) with a 
purified virus recombinant VP2 protein according 
to the manufacturer’s protocol (Biotrin Ltd, Dublin, 
Ireland). 
Negative B19 infection was defined as the ab-
sence of B19-specific markers; past infection, as 
the presence of IgG class specific antibodies only 
(IgG+) (although in some cases, latent persistent 
infection could not be excluded); latent persistent 
infection, as the presence of IgG class antibodies 
and viral genomic sequences in PBL DNA (IgG+ 
IgM– PBL+); active persistent infection (virus re-
activation), as the presence of IgM and IgG class 
antibodies and viral sequences in PBL DNA and/or 
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plasma DNA (IgM+ IgG+ PV+, IgM+ IgG+ PBL+, 
IgM+ IgG+ PBL+ PV+, IgG+ PV+, and IgG+ PV+ 
PBL+); and primary (acute) infection, as  the pres-
ence of anti-B19 specific IgM class antibodies with 
or without IgG class antibodies and/or viral genom-
ic sequences in plasma DNA (IgM+ IgG– PV–, 
IgM+ PV+, IgM+ IgG+ PV–, IgM+ IgG+ PV+). 
Statistical Analysis. Statistical differences in the 
prevalence of past infection, latent- and active per-
sistent B19 infection before and after RT were as-
sessed by using the MedCalc software for Windows, 
version 12.2.1, and the Fisher exact test. The lo-
gistic regression analysis was performed using the 
SPSS 16.0 for Windows software to assess the re-
lationship between past infection, latent and active 
persistent B19 infection, and moderate and severe 
anemia after RT. A P value of <0.05 was considered 
statistically significant. 
Results 
Clinical Presentation. The mean Hb level in the 
Groups 1 and 2 after RT was 10.03 g/dL (SD, 0.29) 
and 14.81 g/dL (SD, 1.93), respectively. Chronic 
persistent anemia and recurrent anemia were de-
tected in 81.6% and 18.4% of recipients, respec-
tively, from the Group 1 (Table 1). The duration of 
recurrent anemia ranged from 3 to 12 months after 
RT. All the recipients with anemia received intrave-
nous human recombinant erythropoietin (rHuEPO) 
therapy (12 000 units once weekly). In the Group 1, 
81.6% of recipients had moderate anemia (Hb level, 
10.7 g/dL [SD, 1.67] ) and 18.4% had severe post-
transplant anemia (Hb level, 8.8 g/dL [SD, 1.12]). 
The recipients with severe anemia received rHuEPO 
therapy (mean dosage, 6000 IU per week subcutane-
ously) during a mean duration of 11.2 months (SD, 
2.4) after RT. rHuEPO therapy failed to raise the Hb 
level in 1 recipient, while in 6 recipients, a short-term 
(within 1–2 months) positive effect was observed. 
There were no significant differences in the per-
centages of patients receiving the induction ther-
apy with basiliximab or ATG comparing both the 
groups (P=0.054 and P=0.372, respectively) (Ta-
ble 1). No significant difference was also detected 
in the frequency of biopsy-proven AR between pa-
tients in the Groups 1 and 2 (P=0.181) (Table 1). 
Chronic allograft dysfunction after RT was observed 
in 34.2% of recipients in the Group 1 and 16% of 
recipients in the Group 2 (P=0.119) (Table 1). Five 
recipients with anemia and chronic allograft dys-
function in the Group 1 lost allograft and were given 
chronic dialysis therapy again. None of the recipi-
ents with chronic allograft dysfunction in the Group 
2 lost allograft (Table 1). 
None of the recipients underwent bone marrow 
biopsy. The causes of anemia after RT, such as gas-
trointestinal bleeding, iron/vitamin B12 deficiency, 
hemolysis, and drug toxicity, were ruled out.
Prevalence of B19 Infection in Renal Transplant 
Donors. Serological and virological testing revealed 
that 83.0% of renal transplant donors had B19 in-
fection: 68.1% had past infection, 10.6% had latent 
persistent infection, and 4.3% had active persistent 
infection. Of the 47 donors, no B19 infection was 
documented in 17.0% (Table 2).
Prevalence of B19 Infection in Patients Before Re-
nal Transplantation. B19 infection before RT was 
detected in 55 (87.3%) of the 63 patients (Table 2). 
Past infection was documented in 28 of the 38 pa-
tients in the Group 1; latent persistent infection, in 
4; active persistent infection, in 2; and no B19 in-
fection was detected in 4 patients (Table 2). In the 
Group 2, of the 25 patients, 20 had past B19 infec-
tion, 1 patient had latent persistent infection, and 
none had active viral infection. No significant dif-
ference in the frequency of past infection and latent 
persistent infection between the Group 1 and the 
Group 2 was found (P=0.566 and P=0.367, respec-
tively) (Table 2). Four patients of each group had no 
markers of B19 infection (P=0.526).
Of the 28 patients with past B19 infection be-
fore RT in the Group 1, 25 received allograft from 
the donors with past infection; 1 patient, from the 
donor with active persistent infection (IgM+ IgG+ 
PBL+); and 2 patients, from the donor without B19 
infection (Table 2). All 4 patients with latent persis-
tent infection received transplants from the donors 
with latent persistent infection. Two patients with 
active persistent infection (IgM+ IgG+ PV+) re-
ceived transplants from the donors with latent per-
sistent infection. Of the 4 patients without markers 
of B19 infection before RT, 1 received the trans-
plant from the donor with active persistent viral 






















Moderate anemia 31 (81.6) 0 (0)
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infection, and 2 patients from the donors without 
B19 infection.
In the Group 2, of the 20 recipients with past 
infection before RT, 19 received transplants from 
the donors with past infection, and 1 from the donor 
without B19 infection; the only patient with latent 
persistent infection received the transplant from the 
B19 infection-negative donor. Four patients without 
B19 infection received transplants from B19 infec-
tion-negative donors (Table 2).
Frequency of Active B19 Infection in Recipients 
After Transplantation. Active B19 infection after RT 
was detected only in the recipients in the Group 1, 
and its frequency was significantly higher than be-
fore RT (31.6% and 5.3%, respectively; P=0.009) 
(Table 2). Primary B19 infection after RT was de-
tected in 2 recipients, and active persistent infection 
(reactivation) was documented in 10 recipients. The 
characteristics of these 12 recipients and their do-
nors are present in Table 3. In 2 recipients negative 
for B19 infection before RT (recipients 3 and 4), 
who received transplants from the donors with B19 
infection, viral genomic sequence in plasma DNA 
and IgM class antibodies associated with primary 
viral infection were detected. All 10 recipients with 
active persistent B19 infection (reactivation) after 
RT had viral infection before RT (6 had past infec-
tion, 2 had latent persistent infection, and 2 persis-
tent plasma viremia before and after RT), and 8 of 
them received transplants from the donors with B19 
infection (Table 3). A possibility reinfection cannot 
be excluded in the recipient 5 with past infection 
before RT who received an allograft from the donor 








Donors 32 (68.1%) 5 (10.6%) 2 (4.3%) 0 (0%) 8 (17%)
Group 1 (n=38)
Before RT 28 (73.7%) 4 (10.5%) 1 (2.6%) 1 (2.6%) 4 (10.5%)
Allograft D+/R+ (26/28)
D–/R+ (2/28)
D+/R+ (4/4) D+/R+ (1/1) D+/R+ (1/1) D+/ R– (2/4) 
D–/R– (2/4)
After RT 20 (52.6%) 4 (10.5%) 10 (26.3%) 2 (5.3%) 2 (5.3%)
Group 2 (n=25)
Before RT 20 (80%) 1 (4%) 0 (0%) 0 (0%) 4 (16%)
Allograft D+/R+ (19/20, 95%)
D–/R+ (1/20, 5%)
D–/R+ (1/1) 0 (0%) 0 (0%) D–/R– (4/4)
After RT 20 (80%) 1 (4%) 0 (0%) 0 (0%) 4 (12%)
RT, renal transplantation.
Table 2. Detection of B19 Infection in the Transplant Donors and Recipients Before and After Renal Transplantation 
Patient 
No.










Transplant Donors Patients Before RT Patients After RT
Antibodies Viral DNA Antibodies Viral DNA Antibodies Viral DNA
IgG IgM PBL PL IgG IgM PBL PL IgG IgM PBL PL
1 + – + – – + – + – + – + 10.1 (0.34) – + +
2 + – + – + + – + + + – + 11.0 (1.01) – + –
3 – + + – – – – – – + – + 7.4 (1.61) + + –
4 + – + – – – – – – + – + 8.1 (0.24) + + +
5 + + + – + – – – + + – + 6.9 (1.69) + + –
6 + – – – + – + – + + – – 11.2 (0.12) – – –
7 + – – – + – – – + + + – 10.6 (1.39) – – –
8 + – – – + – – – + + + + 9.1 (2.04) – + –
9 + – – – + – + – + + – + 7.3 (2.15) + + +
10 + – – – + – – – + + + – 10.6 (1.13) – – –
11 – – – – + – – – + + – + 7.4 (0.24) + + –
12 – – – – + – – – + + – + 9.7 (1.31) – – –
PBL, peripheral blood leukocytes; PL, blood plasma; AR, acute rejection; RT, renal transplantation; +, positive results; 
–, negative results.
Table 3. Characteristics of Recipients With Active B19 Infection Before and After Renal Transplantation
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of the 25 recipients in the Group 2 had active viral 
infection (Table 2).
Of the 13 recipients with delayed graft function 
in the Group 1, active B19 infection was observed 
in 8 recipients; 3 of them lost the allograft and were 
given chronic dialysis therapy again (Tables 1 and 
3); however, the immunohistochemical analysis of 
transplants is required to confirm a relationship 
between B19 infection and chronic transplant dys-
function.
B19 Infection and Anemia of Different Grade. 
Moderate anemia after RT was documented in 31 
of the 38 recipients. A total of 22 recipients had 
past infection, 2 had latent persistent infection, 5 
had active persistent infection, and 2 recipients did 
not have any markers of B19 infection. The logistic 
regression analysis revealed no significant associa-
tions between past infection, latent persistent infec-
tion, and active persistent infection and moderate 
anemia. 
rHuEPO therapy-resistant severe anemia after 
RT was observed in 7 of the 12 recipients with ac-
tive B19 infection. Primary viral infection and ac-
tive persistent infection was diagnosed in 2 and 5 of 
the 7 recipients, respectively. The logistic regression 
analysis revealed a significant relationship between 
active B19 infection and severe anemia (OR, 0.039; 
95% CI, 0.006–0.257; P=0.001).
Discussion
Chronic anemia is one of the clinical manifesta-
tions of B19 infection in immunosuppressed indi-
viduals. The presence of anemia after renal trans-
plantation is well-known; however, specific data on 
frequency and risk factors are scarce. The preva-
lence of B19 infection is difficult to estimate since 
the majority of reports are case reports rather than 
carefully monitored cohort studies. Furthermore, 
the interpretation of published data is difficult due 
to the selection of different criteria, different defini-
tions of latent, persistent, and active infection, and 
various lengths of follow-up period.
The obtained results demonstrate that B19 sero-
prevalence in renal transplant donors and patients 
(83% and 84.1%, respectively) is similar to that in 
the overall population (40%–80%) (17, 18). The 
presence of IgG, but not IgM class, specific antibod-
ies most likely represents past infection, although 
possibly latent persistent B19 infection in these in-
dividuals could not be excluded. The observation 
of B19 reactivation in 2 IgG-positive patients before 
RT who received the transplants from the virus-
negative donors indicates that they had latent per-
sistent B19 infection before RT despite the lack of a 
virus-specific sequence in PBL DNA.
Active persistent B19 infection was detected in 
2 of the 47 donors and 1 of the 38 anemic patients 
before RT, but its significantly higher frequency 
was documented in the anemic patients after RT 
(12/38). The lack of IgG class antibodies in 3 of the 
12 IgM-positive patients allows suggesting that they 
were functionally deficient or their quantity is insuf-
ficient for virus neutralization. One patient with the 
transplant dysfunction had active persistent infec-
tion during the overall follow-up period after RT 
despite the presence of IgG class antibodies that also 
could be due to the functional deficiency of these 
antibodies or their insufficient quantity for virus 
neutralization. Another patient with the transplant 
dysfunction accompanied by transplant loss had no 
IgG class antibodies and most likely had active per-
sistent infection, since the presence of IgM class an-
tibodies and plasma viremia were documented dur-
ing the overall follow-up period after RT. However, 
the deregulation of the humoral immunity could 
not be excluded as well. These suggestions are con-
sistent with the findings of other investigations (13, 
19, 20).
In our study, severe anemia was diagnosed in 9 
of the 38 recipients after RT who failed to respond 
to the repeated rHuEPO administration, and 7 of 
them had active persistent B19 infection. Similarly 
Egbuna et al. (21) have shown the presence of active 
B19 infection in 38% of recipients with erythropoi-
etin-resistant severe anemia.
The detection of primary B19 infection in 2 re-
cipients without the markers of B19 infection before 
RT, who received the transplants from the donors 
with latent persistent viral infection, shows a pos-
sible transmission of the virus via transplant, which 
could be a virus persistency site. Yango et al. re-
ported donor-transmitted B19 infection in a renal 
transplant recipient (22).
In our study, active B19 infection was docu-
mented in 8 of the 17 recipients with chronic al-
lograft dysfunction. These results are in accordance 
with those of Cavallo et al. (10), who reported that 
36% of patients with active B19 infection had an 
elevated serum creatinine level after RT. In contrast, 
Ki et al. (23) did not find any relationship between 
allograft dysfunction and B19 infection.
Conclusions
Active B19 infection was documented only in 
the anemic recipients and could be associated with 
the development of severe anemia after renal trans-
plantation. This allows us to recommend concurrent 
screening for viral DNA in plasma and detection of 
anti-B19 IgM class antibodies. To find the associa-
tion between B19 infection and the development of 
anemia, further investigations are necessary.
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